Skip to main content
Skip to content
Case File
efta-efta01196657DOJ Data Set 9Other

DS9 Document EFTA01196657

Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01196657
Pages
2
Persons
0
Integrity
No Hash Available

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
GIO GLOBAL INVESTMENT OPPORTUNITIES GIO Market Alert March 2015 Increasingly the market appears to be coming around to our view that not only is the Fed likely to hike in 2015 but the timing of that hike is likely to be in the next 3-6 months (i.e. June or September). While we view this as a positive sign and affirmation that the US economy is solidly expanding, equity markets can be choppy in the months around the beginning of a tightening cycle as markets digest the news. Looking back 30 years, the S&P 500 has typically been rangebound in the months before the first Fed hike with peak-to-trough drawdowns ranging from 5-10%. Furthermore, our views on continued US dollar strength and oil weakness as it re-tests recent lows could drive additional concerns on corporate earnings. With this in mind, we think it is prudent to take profits on some of our US equity exposure which has done well over the last 3 years to take down risk in the US. We will look for the right opportunity to reinvest this dry powder when market volatility increases. WHERE TO TAKE PROFITS Large Cap Outperformers There are many companies that have outperformed in the last 6-9 months and as a result now have a smaller valuation cushion. We would take profits on those outperformers, particularly those up over 10% in 2015 in the large cap technology and pharma sectors that lack catalysts in the next 3- 6 months. We expect to buy them back on a —10% pullback. Payments Innovation Since the announcement of Apple Pay in September 2014, the stocks we highlighted as beneficiaries of mobile payments innovation are up 14% due to strong results and underlying trends. While we still like many of the companies longer term, the credit card networks and NFC chip makers may become more volatile in the near term. Life Sciences Last year we highlighted an opportunity in Life Sciences, particularly those focusing on genetic testing. While we still like some companies longer term, we believe the primary catalyst around reduced sequencing costs has played out in the near term and are taking profits on the stock basket up 12% since inception in February 2014 with some individual stocks up over 30%. For clients interested in maintaining exposure to the theme, we would focus on hardware manufacturers. Source: Bloomberg. As of March 2015. WHAT WE'RE HOLDING ON TO Hedged European Equities and Short EUR With the ECB engaging in quantitative easing (QE) we think the pressure remains for euro to continue weakening and may last well below parity. We expect European equities to remain supported with investors following the US QE playbook. While European equities could experience some volatility, it could be tempered by continued investor flows. Hedged Japanese Equities Recent improvements in Japanese macro fundamentals keep us invested in Japanese equities. There may also be potential catalysts around an equity-geared increase in QE and flows benefits from continued shifts into equities by asset allocators following the GNPs lead. US Banks While recognizing that US bank stocks will not be fully immune to market beta, as a sector bank valuations remain low in a historical context and capital returns to shareholders seem to be increasing following the recent CCAR (Comprehensive Capital Analysis and Review) results. Furthermore, the sector should broadly benefit from Fed hikes and as a result we would maintain exposure to this sector, especially to the regional banks, even through near term volatility. Anton Pil Jeanne Sun Peter Epstein Investment products: Not FDIC insured • No bank guarantee • May lose value EFTA01196657 GIO GLOBAL. INVESTMENT OPPORTUNITIES IMPORTANT INFORMATION This presentation and the material contained herein is not a product of the J.P. Morgan Research Department and is not a research report, although it may refer to a research report or research analyst. This presentation should be reviewed in conjunction with U.S. research published by.I.P. Morgan Securities, LLC to the extent that such research exists. The opinions and ideas expressed herein do not take into account individual client circumstances, objectives and needs. Transactions in any securities that may be referenced herein may not be suitable for all investors. This presentation has been prepared for information purposes only. Nothing in this material is intended to be a solicitation for any product or service offered by.I.P. Morgan's Private Bank or any of its affiliates. Information contained herein has been obtained from sources believed to be reliable but we do not guarantee its accuracy or completeness and accept no responsibility for any direct or consequential losses arising from its use. The views and strategies described herein may not be suitable for all investors. This information is not intended as an offer or solicitation for the purchase or sale of any financial instrument and is being provided merely to illustrate a particular investment strategy. Past performance is no guarantee of future result. This material contains certain information/statistics that hove been obtained from sources deemed reliable, but J.P. Morgan Securities does not guarantee their accuracy or completeness. Past performance is not a guarantee of future results, and information is subject to change at any time. Bank products and services are offered through JPMorgan Chase Bank, NA. and its affiliates. Securities are offered by.I.P. Morgan Securities LLC and Clearing and Custody by 1.P. Morgan Clearing Corp., both are members of FINRA, NYSE and SIPC.J.P. Morgan Securities LLC and J.P. Morgan Clearing Corp are affiliates of JPMorgan Chase Bank, N.A. Investment products: Not FDIC insured • No bank guarantee • May lose value EFTA01196658

Technical Artifacts (2)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

SWIFT/BICINFORMATION
Wire Refreferenced

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.